OBJECTIVES: The current study tested the hypothesis that glucose utilization differs between visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), and investigated potential mechanisms for such a finding. BACKGROUND: VAT burden correlates better with cardiovascular risk than does SAT burden. Beyond volumetric measurement, glucose uptake in adipose tissue (AT) might reflect metabolic activity and provide pathophysiologic insight and aid risk stratification. METHODS: We retrospectively studied tissue-specific glucose uptake in vivo in clinically obtained whole-body fluorodeoxyglucose positron emission tomography (FDG-PET) scans in humans. We also assessed glucose uptake in vitro, using stromal vascular cells isolated from SAT and VAT of diet-induced obese C57BL/6 mice. Quantitative polymerase chain reaction (PCR) evaluated the expression of multiple genes involved in cellular glucose metabolism, including glucose transporters (GLUT-1, -3, and -4) and hexokinases (HK-1 and -2) in SAT and VAT of obese C57BL/6 mice. RESULTS: We analyzed whole-body FDG-PET scans from 31 obese and 26 lean patients. VAT exhibited higher FDG uptake compared with SAT (p < 0.0001) independent of age, sex, body mass index, comorbidities, and medications. To investigate mechanisms underlying this observation, we studied glucose uptake in the stromal vascular cell fraction of AT, which is rich in inflammatory cells. Stromal vascular cells from VAT of diet-induced obese C57BL/6 mice exhibited higher glucose uptake than those from SAT (p = 0.01). Evaluation of expression of glucose transporters (GLUT-1, -3, and -4) and hexokinases (HK-1 and -2), revealed increased expression of HK-1 in VAT-derived compared with SAT-derived stromal vascular cells, and also in visceral versus subcutaneous unfractionated AT. CONCLUSIONS: In humans in vivo, VAT has increased glucose uptake compared with SAT, as determined noninvasively with FDG PET imaging. Differential stromal metabolic activity may be 1 mechanism underlying differences in metabolic activity of visceral and subcutaneous AT.
OBJECTIVES: The current study tested the hypothesis that glucose utilization differs between visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), and investigated potential mechanisms for such a finding. BACKGROUND: VAT burden correlates better with cardiovascular risk than does SAT burden. Beyond volumetric measurement, glucose uptake in adipose tissue (AT) might reflect metabolic activity and provide pathophysiologic insight and aid risk stratification. METHODS: We retrospectively studied tissue-specific glucose uptake in vivo in clinically obtained whole-body fluorodeoxyglucose positron emission tomography (FDG-PET) scans in humans. We also assessed glucose uptake in vitro, using stromal vascular cells isolated from SAT and VAT of diet-induced obese C57BL/6 mice. Quantitative polymerase chain reaction (PCR) evaluated the expression of multiple genes involved in cellular glucose metabolism, including glucose transporters (GLUT-1, -3, and -4) and hexokinases (HK-1 and -2) in SAT and VAT of obese C57BL/6 mice. RESULTS: We analyzed whole-body FDG-PET scans from 31 obese and 26 lean patients. VAT exhibited higher FDG uptake compared with SAT (p < 0.0001) independent of age, sex, body mass index, comorbidities, and medications. To investigate mechanisms underlying this observation, we studied glucose uptake in the stromal vascular cell fraction of AT, which is rich in inflammatory cells. Stromal vascular cells from VAT of diet-induced obese C57BL/6 mice exhibited higher glucose uptake than those from SAT (p = 0.01). Evaluation of expression of glucose transporters (GLUT-1, -3, and -4) and hexokinases (HK-1 and -2), revealed increased expression of HK-1 in VAT-derived compared with SAT-derived stromal vascular cells, and also in visceral versus subcutaneous unfractionated AT. CONCLUSIONS: In humans in vivo, VAT has increased glucose uptake compared with SAT, as determined noninvasively with FDG PET imaging. Differential stromal metabolic activity may be 1 mechanism underlying differences in metabolic activity of visceral and subcutaneous AT.
Authors: Kirsi A Virtanen; Patricia Iozzo; Kirsti Hällsten; Risto Huupponen; Riitta Parkkola; Tuula Janatuinen; Fredrik Lönnqvist; Tapio Viljanen; Tapani Rönnemaa; Peter Lönnroth; Juhani Knuuti; Ele Ferrannini; Pirjo Nuutila Journal: Diabetes Date: 2005-09 Impact factor: 9.461
Authors: Kirsi A Virtanen; Peter Lönnroth; Riitta Parkkola; Pauliina Peltoniemi; Markku Asola; Tapio Viljanen; Tuula Tolvanen; Juhani Knuuti; Tapani Rönnemaa; Risto Huupponen; Pirjo Nuutila Journal: J Clin Endocrinol Metab Date: 2002-08 Impact factor: 5.958
Authors: Stuart P Weisberg; Daniel McCann; Manisha Desai; Michael Rosenbaum; Rudolph L Leibel; Anthony W Ferrante Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: S Perrini; L Laviola; A Cignarelli; M Melchiorre; F De Stefano; C Caccioppoli; A Natalicchio; M R Orlando; G Garruti; M De Fazio; G Catalano; V Memeo; R Giorgino; F Giorgino Journal: Diabetologia Date: 2007-10-25 Impact factor: 10.122
Authors: Stacy A Porter; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; Christopher J O'Donnel; Caroline S Fox Journal: Diabetes Care Date: 2009-02-24 Impact factor: 19.112
Authors: Stefanie A de Boer; Daan S Spoor; Riemer H J A Slart; Douwe J Mulder; Melanie Reijrink; Ronald J H Borra; Gerbrand M Kramer; Otto S Hoekstra; Ronald Boellaard; Marcel J Greuter Journal: Mol Imaging Biol Date: 2019-02 Impact factor: 3.488
Authors: Christophe Van de Wiele; Mathias Van Vlaenderen; Ludovic D'Hulst; Anne Delcourt; Dominique Copin; Bart De Spiegeleer; Alex Maes Journal: Eur J Nucl Med Mol Imaging Date: 2016-10-11 Impact factor: 9.236
Authors: Andrew M Kim; Brendan T Keenan; Nicholas Jackson; Eugenia L Chan; Bethany Staley; Drew A Torigian; Abass Alavi; Richard J Schwab Journal: Am J Respir Crit Care Med Date: 2014-06-01 Impact factor: 21.405
Authors: Joyce Veld; Elizabeth K O'Donnell; Michaela R Reagan; Andrew J Yee; Martin Torriani; Clifford J Rosen; Miriam A Bredella Journal: Skeletal Radiol Date: 2016-06-25 Impact factor: 2.199
Authors: Martin Torriani; Markella V Zanni; Kathleen Fitch; Eleni Stavrou; Miriam A Bredella; Ruth Lim; Aaron M Cypess; Steven Grinspoon Journal: Antivir Ther Date: 2012-10-05